¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ,x]xtg?  
N5%Cwl6i  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 24; BY'   
YB?5s`vr9d  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© muZ6}&4  
-V\$oVS0S  
1.Co-stimulators (or co-stimulating molecules) cZFG~n/  
^:Hx.  
2.NK-kB gOSFvH8FU  
r,FPTf  
3.Immunoglobulin superfamily &X`zk  
,+mH1#-3  
4.antigen-presenting cell (APC) =TcT`](o  
#J_+ SL[  
5.death domain BnwYyh  
+yO^,{8SE  
6.CCR and CXCR 4eh~/o&h  
Q}qw` L1  
7.Lectin (or mitogen) piPx8jT`F  
.9'bi#:Cw  
8.Clusters of differentiation, CD) {<J(*K*\Jo  
uNoP8U%*  
9.B7 family A-GU:B  
~;ZT<eCIA  
10.Cytotoxic T lymphocyte, CTL) =e j'5m($3  
Zy+EI x  
11.IL-15 and IL-15 receptor (IL-15R) ]\ DIJ>JZ  
P"k`h=>!4  
12.MHC restriction '}pe$=  
YuVg/ '=  
13.Affinity-chromatography ?K9zTas@  
[e.@Yx_}  
14.Cyctosprin A, CsA ?K>=>bS^h  
?]In@h-  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) </@3}rfUPg  
vOnhJN  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 1.6Y=Mh=i[  
?x-:JME0  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Fmo^ ?~b  
eJ2$DgB}t  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ckCb)r_  
[:xpz,  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ >?yxig:_  
/~nPPC  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© +GDT@,/  
|o0?u:  
ÃâÒßѧרҵ£º < X&{6xu  
L,PD4H"8  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ KBSO^<7  
530Z> q  
Ïû»¯ÄÚ¿Æ£º *!p#1fE  
4y$tp1 8  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ /QT"5fxKJ  
/ltGSl  
ѪҺ²¡Ñ§×¨Òµ£º WK)2/$7@  
),53(=/hl  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»